Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459243 | 1.00 | HTR6 (0.36) | HTR6POLBL3MBTL1 | |
| SCHEMBL5504078 | 0.83 | HTR6 (0.34) | HTR6 | |
| SCHEMBL5504074 | 0.83 | HTR6 (0.34) | HTR6 | |
| SCHEMBL4465966 | 0.77 | PSIP1 (0.36) | — | |
| SCHEMBL4465969 | 0.77 | PSIP1 (0.36) | — | |
| SCHEMBL4474579 | 0.76 | BRD4 (0.38) | — | |
| SCHEMBL4474572 | 0.76 | BRD4 (0.38) | — | |
| SCHEMBL4463051 | 0.74 | SMN1; SMN2 (0.36) | POLBL3MBTL1 | |
| SCHEMBL4463046 | 0.74 | SMN1; SMN2 (0.36) | POLBL3MBTL1 | |
| SCHEMBL4460358 | 0.72 | MAPT (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | claimed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | claimed |
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041137-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | HTR6 3051/4885POLB 943/4885L3MBTL1 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.